Schizophrenia
Conditions
Interventions
1)PET, MRI, blood concentration 2)blonanserin 8 to 24mg po, for 2 weeks, PET, MRI, blood concentration
1)PET, MRI, blood concentration 2)olanzapine 2.5 to 20mg po, for 2 weeks, PET, MRI, blood con
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patinet who was diagnosed as schizophrenia by DSM-IV-TR - Patinet with PANSS score is less than 120 at the screening - Patient who has been taking single administration of olanzapine, the dose was not changed at least more than 2 weeks, at least 4 weeks before the test. Or drug-naive patient. - Subjects who have the ability to provide informed consent and adhere to the protocol.
Exclusion criteria
Exclusion criteria: - with past or current history of serious medical illness and/or brain organic diseases - subject who is contraindicated for the use of MRI - with past or current history ofsevere liver disease, kidney disease, heart disease, allergy, or severe drug allergy - contraindication for blonanserin - treated by electroconvulsive therapy within 3 months before the screening. - taking tandspirone at the screening. - subject who are judged as not suitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the dopamine D2 and D3 receptor occupancy of antipsychotics will be assessed after taking antipsychotics for 2 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| blood concentration, MRI, neuropsychological test | — |
Countries
Japan
Contacts
Public ContactAmane Tateno
Nippon Medical School Department of Neuropsychiatry
Outcome results
None listed